{"organizations": [], "uuid": "b5881f00853c6bda80b6525b411dbc4ef2ccabc4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-us-fda-grants-priority-review-for/brief-u-s-fda-grants-priority-review-for-supplemental-new-drug-application-for-xtandi-idUSASC09SVR", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T22:49:00.000+02:00", "replies_count": 0, "uuid": "b5881f00853c6bda80b6525b411dbc4ef2ccabc4"}, "author": "", "url": "https://www.reuters.com/article/brief-us-fda-grants-priority-review-for/brief-u-s-fda-grants-priority-review-for-supplemental-new-drug-application-for-xtandi-idUSASC09SVR", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "new drug application for xtandi reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "astellas pharma inc", "sentiment": "none"}, {"name": "crpc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 19, 2018 / 8:50 PM / Updated 12 minutes ago BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi Reuters Staff 1 Min Read March 19 (Reuters) - Astellas Pharma Inc: * U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) * ASTELLAS PHARMA INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE ASSIGNED BY FDA IS JULY 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-19T22:49:00.000+02:00", "crawled": "2018-03-19T23:09:07.002+02:00", "highlightTitle": ""}